Canadian biotechnology company Zenith Epigenetics has teamed up with Cencora, previously known as AmerisourceBergen, to advance the commercialisation of its ZEN-3694 programme.

Under the terms of the partnership agreement, Cencora will support the development of strategies for the market release of ZEN-3694.

The collaboration will initially focus on providing insights into potential barriers and opportunities for the launch of ZEN-3694, which will be used to customise its development.

Zenith will continue to work on the technology platform, while Cencora will explore opportunities for the commercialisation and market roll-out of the ZEN-3694 program.

Zenith chairman, founder, and CEO Donald McCaffrey said: “We know that ZEN-3694 will innovate the future of oncology and are proud to work with Cencora on the next steps of bringing ZEN-3694 into the lives and homes of patients nationwide and, in time, globally.”

“For a product with the immense capabilities ZEN-3694 has, we knew we needed a partner with immeasurable experience across healthcare, unmatched distribution capabilities, and a global impact.

“Cencora emerged as the best partner to lead the commercial and distribution strategy for ZEN-3694 with innovation, strategic thinking, and careful planning around patient access and the patient experience.”

Zenith is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics for the treatment of cancer and other disorders.

ZEN-3694 is its lead compound, currently in clinical development for various oncologic indications and several studies sponsored by collaborators.

The existing partners and collaborators include Pfizer, Merck, BMS, Eli Lilly, Astellas, GSK, and Syndax.

ZEN-3694 is also supported by the National Cancer Institute, National Institute of Health, Dana Farber-Harvard, Yale, UCSF, Memorial Sloan Kettering, and MD Anderson.

Cencora is a global pharmaceutical company that partners with drugmakers across the value chain to facilitate and optimise market access to therapies.

Cencora International commercialisation senior vice president Sandra Anderson said: “As biotech and pharmaceutical companies invest in the development of new products, we remain focused on delivering integrated support across the clinical and commercialisation journey to help them bring their innovations to market.

“We are thrilled to support Zenith’s pre-commercial launch preparations and will provide the solutions they need to help them accelerate time-to-market and maximise commercial success.”